References
- Bandmann O, Weiss KH, Kaler SG. (2015). Wilson’s disease and other neurological copper disorders. Lancet Neurol 14:103–13.
- Brewer GJ, Askari F, Dick RB, et al. (2009). Treatment of Wilson's disease with tetrathiomolybdate: V. Control of free copper by tetrathiomolybdate and a comparison with trientine. Transl Res 154:70–7.
- Bull PC, Thomas GR, Rommens JM, et al. (1993). The Wilson disease gene is a putative copper transporting P-type ATPase similar to the Menkes gene. Nat Genet 5:327–37.
- European Association for Study of Liver. (2012). EASL Clinical Practice Guidelines: Wilson's disease. J Hepatol 56:671–85.
- Komatsu Y, Sadakata I, Ogra Y, Suzuki KT. (2000). Excretion of copper complexed with thiomolybdate into the bile and blood in LEC rats. Chem Biol Interact 124:217–31.
- Lowndes SA, Adams A, Timms A, et al. (2008). Phase I study of copper-binding agent ATN-224 in patients with advanced solid tumors. Clin Cancer Res 14:7526–34.
- Ogra Y, Ohmichi M, Suzuki KT. (1995). Systemic dispositions of molybdenum and copper after tetrathiomolybdate injection in LEC rats. J Trace Elem Med Biol 9:165–9.
- Ogra Y, Chikusa H, Suzuki KT. (2000). Metabolic fate of the insoluble copper/tetrathiomolybdate complex formed in the liver of LEC rats with excess tetrathiomolybdate. J Inorg Biochem 78:123–8.
- Pfeiffer RF. (2007). Wilson's disease. Semin Neurol 27:123–32.
- Roberts EA, Schilsky ML. (2008). Diagnosis and treatment of Wilson disease: an update. Hepatology 47:2089–111.
- Smirnova J, Kabin E, Järving I, et al. (2018). Copper(I)-binding properties of de-coppering drugs for the treatment of Wilson disease. α-lipoic acid as a potential anti-copper agent. Sci Rep 8:1463.
- Suzuki KT, Yamamoto K, Ogra Y, et al. (1994). Mechanisms for removal of copper from metallothionein by tetrathiomolybdate. J Inorg Biochem 54:157–65.
- Weiss KH, Gotthardt DN, Klemm D, et al. (2011). Zinc monotherapy is not as effective as chelating agents in treatment of Wilson disease. Gastroenterology 140:1189–98.
- Weiss KH, Thurik F, Gotthardt DN, et al. (2013). Efficacy and safety of oral chelators in treatment of patients with Wilson disease. Clin Gastroenterol Hepatol 11:1028–35.
- Weiss KH, Askari FK, Czlonkowska A, et al. (2017). Bis-choline tetrathiomolybdate in patients with Wilson's disease: an open-label, multicentre, phase 2 study. Lancet Gastroenterol Hepatol 2:869–76.